|Dr. Neil Kumar||CEO & Director||247.68k||N/A||1979|
|Dr. Uma Sinha||Chief Scientific Officer & Director||533.4k||N/A||1957|
|Dr. Cameron Turtle Ph.D.||Chief Bus. Officer||578.4k||N/A||1990|
|Dr. Jonathan C. Fox FACC, M.D., Ph.D.||Pres & Chief Medical Officer||N/A||N/A||1957|
|Dr. Isabella Graef M.D.||Co-Founder & Board Advisor||N/A||N/A||1965|
|Dr. Mamoun Alhamadsheh Ph.D., Pharm.D.||Co-Founder||N/A||N/A||N/A|
|Mr. Franco Valle||Sr. VP of Fin., Principal Accounting Officer & Sec.||N/A||N/A||1981|
|Mr. Matt Outten||Chief Commercial Officer||N/A||N/A||N/A|
|Dr. Hoyoung Huh||Consultant||N/A||N/A||1969|
Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.
Eidos Therapeutics, Inc.’s ISS Governance QualityScore as of November 1, 2019 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder Rights: 5; Compensation: 8.